DIsease Description
Chronic Pain is a very broad medical disorder comprised of many different pain syndromes and underlying reasons for the symptoms[1]. Pain is influenced by many different elements other than physical neural inputs including the brain, emotional and social factors. As a result acute pain differs from chronic pain and cancer related pain differs from non-malignant pain, making comparison between these different groups important when determining what treatment to use[2].
The International Association for the Study of Pain defines chronic pain as pain persisting beyond the normal tissue healing time (3 - 6 months) [3]. Chronic pain is associated with an abnormal neuron responsiveness or increased gain of nerve pathways to the brain, as well as with alterations in the brains interpretation of the signals[2].
In this group we are specifically referring to chronic pain that is not a result of cancer.
Disease Prevelance
The prevalence of non-specific chronic pain in the general population is reported to be as high as 55%[4,5].
Current Treatment Options
Chronic pain remains a very task for today's doctors due to a lack of effective treatments. Controversially opioids have been and continue to be regularly prescribed in chronic pain treatment. There are very serious concerns about their long-term effectiveness and the major issue of addiction [6]. Evidence suggests that in some patients long term opioid exposure may actually worsen a patients pain[2].
Evidence for and Proposed Mechanism of Action of Cannabinoid Therapeutics
In a study in Spain, the evidence that pain states alter the endocannabinoid receptor system at key sites involved in pain processing is discussed, and how the changes may inform the development of cannabinoid-based analgesics. According to this study, "cannabinoid ligands produce well documented analgesic effects mediated by the CB1 and CB2 receptors; however, other receptor systems may also contribute, in particular in inflammatory and neuropathic pain states. The emerging evidence that the levels of cannabinoid receptors, their ligands and biologically active metabolites are altered in a tissue-specific manner under pathological conditions, such as chronic pain states, may support a more targeted approach to the development of cannabinoid-based analgesics."[8]
There has been a lot of encouraging research surrounding the issue of cannabinoid treatments for chronic pain. Animal studies using either acute or chronic pain models have demonstrated significant pain relieving effects of Cannabinoids. However, the role of CBs in human analgesia or antihyperalgesia is less well documented [7].
In a systematic review by De Vries et a. it was stated that, "The introduction of CB (cannabinoid) medicines offers an interesting alternative approach in the area of chronic pain management, particularly for cases in which currently available pharmacological treatments are not sufficient. Scientific literature on clinical research regarding medicinal CBs lags far behind the extensive anecdotal experiences of both patients and their physicians. The majority of clinical trials in patients with chronic non-malignant pain summarized in this review reported improvement in pain scores in favor of products containing dronabinol."[2] 1. Beaulieu P, Ware M. Reassessment of the role of cannabinoids in the management of pain. Curr Opin Anaesthesiol 2007;20(5):473-7
2. de Vries et al. Dronabinol and chronic pain: importance of mechanistic considerations. Expert Opin. Pharmacother. (2014) 15(11):1525-1534
3. Merskey H, Bogduk N. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. 2013. International Association for the Study of Pain (IASP), Task Force on Taxonomy, Seattle 1994
4. Andersson HI, Ejlertsson G, Leden I, Rosenberg C. Chronic pain in a geographically defined general population: studies of differences in age, gender, social class, and pain localization. Clin J Pain. 1993;9(3):174-82.
5. Elliott AM, Smith BH, Penny KI, Smith WC, Chambers WA. The epidemiology of chronic pain in the community. Lancet. 1999 Oct; 354(9186):1248-52.
6. Noble M, Tregear SJ, Treadwell JR, Schoelles K. Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage 2008;35(2):214-28
7. Karst M, Wippermann S, Ahrens J. Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs 2010;70(18):2409-38
8. Sagar, Devi Rani et al. “Dynamic Regulation of the Endocannabinoid System: Implications for Analgesia.” Molecular Pain 5 (2009): 59. PMC. Web. 20 Nov. 2014.
We are LIVE !!! Join the FIGHT NOW! with Harvard Award Winning,
Low-Cost Cancer-Killing Treatments! Click the Above Image link to setup your Account and begin your Crypto Journey with us. The 1-Million Strong Killing Cancers Foundation, the 1-Million Strong Fight Club, & CSi Labs are making cancer treatments affordable and accessible for millions of patients through our innovative cancer killing fundraising meme token. All Crypto MEME Coin Purchases will be included in the Up and Coming Contests and Promotions!
The Time is Now. 1-Million Strong Killing Cancers!
Click the Below Image to Review our Cancer Drug Comparables
*** Warning this document contains graphic images.
CSi-VIP Awards & NASDAQ Updates
Please Click the Below Image:



The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.
Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.
We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.
Click here to review the Report:
Case No. 2:17-CV-02271-KJM-JDP
Inspire, Dream, Change
YOUR DIGITAL ERA Personal & Business Access Learning HUB
Please Click the Below Calendar image to book your time to speak with Mr. Dabney about Your CSi-VIP Shareholder Legacy & 1-Million Strong Membership.
One LAST TIME … for CLARITY …
CBIS Original Shareholders - CBIS First Rights, CSi-VIP Bonus Shares, CBIS GIFT Shares, CSi-VIP Drug Ownership Program ...
*** CSi-VIP AWARDS Program !!!
MAKE SURE … You have Your CSi-VIP Membership!

Click the Above image: February 4, 2026, Cannabis Science Inc., Shareholder Close-out. All Cannabis Science Shareholders Qualify.
Above ANNOUNCEMENT: December 31, 2025, Cannabis Science Inc., Shareholder Close-out.
Cannabis Science Financials & FINAL CBIS/CSi-VIP Share Numbers. Click the above Image link to view the latest Report.
November 5, 2025
Cannabis Science Shareholder FINAL Audit Confirmations
Click the above Image link to view the latest Report
September 23, 2025
Cannabis Science Shareholder Audit Confirmations Underway now!
Click the above Image link to view the latest Report.
July 7, 2025
Click the above Image link to view the latest cancer Killing promotional video. This is where you can join our 1-Million Strong youtube page to view more videos as we proceed forward.
June 1, 2025, Pre-Launch Success
Click the above Image link to setup your Account and begin your Crypto Journey with us. All Crypto Coin Buyers receive a Limited Time offer!
*** Warning this document contains exciting images.
The FINAL “CBIS GIFT Shares” Issuances!
DECEMBER 2024, Cheers! & HAPPY HOLIDAYS !!!
ALL GIFT Shares 1, 2, & 3 being ISSUED !!!
LAST Steps:
Please confirm Yours NOW !!!
1. CONFIRM Correct Total Share Amount(s)
2. CONFIRM Correct Name(s) on CERTIFICATE
3. CONFIRM Correct Mailing Address
ASU/CSi-EDP-ECO-System
At it's FINEST !!!
WHICH ONE ARE YOU ??
Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???
We can make this HAPPEN way FASTER Working as a TEAM !!!
WHAT Matters is how much you CARE about KILLING CANCERS ...
This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.

2025 Audit considerations NASDAQ.
Cannabis Science Inc.
Share Structure 2025
Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.
Common Stock:
Authorized:
5,000,000,000
Issued:
2,839,095,296
Fully Diluted:
4,510,547,648
Class A Common Stock
Authorized:
100,000,000
Issued:
0
Class B Common Stock
Authorized:
1,500,000,000
Issued:
0
Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000
Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.
You already know our Extensive LIST of GROUNDBREAKING Products.
1-Million STRONG TV Coverage, HARVARD Award Success.
TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE
*** APPLY for FREE in CONFIDENCE and Success.
Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.
EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!
RAYMOND, PLEASE RESPOND TO MY EMAIL! ...Francis G. Cormier III
In 2021, a share exchange was initiated through Thermic Science International...RAYMOND, PLEASE RESPOND TO MY EMAIL! ...Francis G. Cormier III
In 2021, a share exchange was initiated through Thermic Science International Corporation, which acquired Cannabis Science Inc and created new share classes for former shareholders. This transaction effectively transitioned Cannabis Science into a private entity under the Thermic Science umbrella, with the stock trading.
Cannabis Science Inc (formerly CBIS) is delisted and no longer publicly traded, with its shares effectively cancelled following SEC actions.
Delisting and SEC Actions
Cannabis Science Inc was delisted by the SEC due to delinquent filings and failure to meet reporting requirements, after a period of suspension and administrative placement on the Grey Market. The company’s shares were cancelled, and there is no active public trading under its former ticker CBIS (Cannabis Science Inc). The delisting followed regulatory sanctions imposed in October 2019, when the company failed to file timely financial reports, leading to its privatization.
Privatization and Share Exchange
After going private, Cannabis Science ceased issuing quarterly results or investor communications, leaving former shareholders without liquidity. In 2021, a share exchange was initiated through Thermic Science International Corporation, which acquired Cannabis Science Inc and created new share classes for former shareholders. This transaction effectively transitioned Cannabis Science into a private entity under the Thermic Science umbrella, with the stock trading symbol ENDO for the new entity
Current Status
As of 2026, Cannabis Science Inc operates as a private company focused on medical marijuana research and development, including phytocannabinoid-based pharmaceutical products. The company is headquartered in Irvine, California, and has a small team of employees. It continues to engage in research, joint ventures, and corporate development, but its former public shares are no longer active or tradable
Key Takeaways
Cannabis Science Inc is permanently delisted and no longer publicly traded
SEC sanctions and failure to file financial reports were the primary reasons for delisting
Former shareholders may participate in the Thermic Science share exchange, but the original CBIS shares are cancelled.
The company now operates privately, focusing on cannabinoid-based pharmaceutical research.
Investors should note that there is no public market liquidity for the original Cannabis Science shares, and any potential investment would involve the private entity under Thermic Science International Corporation.
Show more